Clinical trials: Heart Failure, Unspecified
- Condition Heart Failure, Unspecified
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure
Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
A prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD).
- Trial name
- NCT02825966
- Testing
- AUDICOR then LifeVest then AUDICOR
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Zoll Medical Corporation
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Heart Failure
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of…
- Trial name
- NCT04630067
- Testing
- AZD3427
- Where
- 10 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cardiac Disease, Heart Failure
Interactive Guided Ultrasound Examinations Done by Non-experts of Ultrasound Imaging
This prospective study is a pilot study for evaluating a guidance system that aims to facilitate high-quality echocardiographic acquisitions.
- Conditions
- Cardiac Disease, Heart Failure, Cardiac Ischemia
- Trial name
- EPISODE (NCT03642730)
- Testing
- TransThoracic Echocardiography imaging
- Where
- France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Heart Failure
Acorai Machine Learning Generalization (MLG) Study
Acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic…
- Trial name
- CAPTURE-HF (NCT05835024)
- Testing
- Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1, Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 1,602 people, healthy volunteers welcome
- Sponsor
- Acorai AB
Hypertension, Heart Failure
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc.
- Trial name
- NCT04967443
- Testing
- Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects
This study will evaluate pharmacokinetics (PK) of four different formulations with different release profiles of AZD9977 (PART A) in the fasted state, and one of the formulation will be selected for further development (Part B).
- Trial name
- NCT03450759
- Testing
- AZD9977 Oral suspension (reference), AZD9977 capsule, AZD9977 ER capsule (fastvrate)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fontan, Right Heart Failure
Cholate Clearance in Fontan and Heart Failure
The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease…
- Trial name
- NCT07009132
- Testing
- Dual cholate clearance assay, MRI
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Cardiovascular Disease
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration
- Trial name
- NCT04686591
- Testing
- AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Essential Hypertension, Chronic Stable Angina
Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- DELIGHT (NCT03063697)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Heart Failure
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Primary objective is to is to evaluate the bioequivalence of two formulations
- Trial name
- NCT06266988
- Testing
- Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Viatris Inc.
Heart Failure
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.
- Trial name
- NCT03318809
- Testing
- AMG 986
- Where
- 4 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
- Trial name
- NCT04763226
- Testing
- BMS-986308, Furosemide
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure
Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography
The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT parameters by SonR technology is able to increase the rate of CRT-D responders, based on significant LV reverse remodeling, as compared to…
- Trial name
- SonR-ECHO (NCT01869062)
- Testing
- SonR CRT Optimization 'On', SonR CRT Optimization 'Off'
- Where
- Canada
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- MicroPort CRM
Heart Failure
AQT90 FLEX NTproBNP2 Test Kit - 23004 - Reference Interval Study
The purpose of this study is to establish the overall (age- and sex independent) at least 95th percentile upper reference limit (URL) of the NTproBNP2 Test Kit on the AQT90 FLEX analyzer.
- Trial name
- RI (NCT06834880)
- Testing
- No intervention; Observational study
- Where
- Finland
- Volunteers
- 781 people, healthy volunteers welcome
- Sponsor
- Radiometer Medical ApS
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Heart Failure
A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy Volunteers
To evaluate the pharmacokinetic properties and safety of "BR1016A" and "BR1016B" in healthy adults.
- Trial name
- NCT05102903
- Testing
- BR1016A, BR1016B
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd